Provided is a low sublimation temperature heterocyclic compound of Chemical Formula 1:

##STR00001## wherein, in Chemical Formula 1, adjacent one or more pairs of * bond to X.sub.1 and X.sub.2 of the following Chemical Formula 2:

##STR00002##

where * means the part of Chemical Formula 1 bonding to X.sub.1 and X.sub.2, and the substituents are as defined in the specification, and an organic light emitting device including the same, whereby the heterocyclic compound of Chemical Formula 1 increases efficiency and stability of the organic light emitting device.

Provided is a low sublimation temperature heterocyclic compound of Chemical Formula 1:

##STR00001## wherein, in Chemical Formula 1, adjacent one or more pairs of * bond to X.sub.1 and X.sub.2 of the following Chemical Formula 2:

##STR00002##

where * means the part of Chemical Formula 1 bonding to X.sub.1 and X.sub.2, and the substituents are as defined in the specification, and an organic light emitting device including the same, whereby the heterocyclic compound of Chemical Formula 1 increases efficiency and stability of the organic light emitting device.

The present invention relates to compounds of formula (1). The compounds are suitable for use in electronic devices, in particular organic electroluminescent devices, comprising these compounds. In some embodiments, the compounds are used as matrix materials for phosphorescent or fluorescent emitters as well as a hole-blocking or electron-transport.

The present invention relates to compounds of formula (1). The compounds are suitable for use in electronic devices, in particular organic electroluminescent devices, comprising these compounds. In some embodiments, the compounds are used as matrix materials for phosphorescent or fluorescent emitters as well as a hole-blocking or electron-transport.

A condensed-cyclic compound is represented by Formula 1, and an organic light-emitting diode includes the condensed-cyclic compound. The organic light-emitting diode includes a first electrode, a second electrode facing the first electrode, and an organic layer. The organic layer includes an emission layer and the condensed-cyclic compound. The condensed-cyclic compound can be included in the emission layer as a host, and the emission layer may further include a dopant. ##STR00001##

A condensed-cyclic compound is represented by Formula 1, and an organic light-emitting diode includes the condensed-cyclic compound. The organic light-emitting diode includes a first electrode, a second electrode facing the first electrode, and an organic layer. The organic layer includes an emission layer and the condensed-cyclic compound. The condensed-cyclic compound can be included in the emission layer as a host, and the emission layer may further include a dopant. ##STR00001##

The present disclosure provides for compounds of formula (I)

##STR00001##

wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

The present disclosure provides for compounds of formula (I)

##STR00001##

wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

The present invention provides a crystal structure of human BTK with space group space group p 2 21 21 and has unit cell parameters a=38.155±2Å; b=72.394±2Å; c=103.946±2Å; a=90°; b=90°; g=90°; the BTK protein is complexed with N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(S)-(6-isobutyl-4-methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide.

The present invention provides a crystal structure of human BTK with space group space group p 2 21 21 and has unit cell parameters a=38.155±2Å; b=72.394±2Å; c=103.946±2Å; a=90°; b=90°; g=90°; the BTK protein is complexed with N-((1R,2S)-2-Acrylamidocyclopentyl)-5-(S)-(6-isobutyl-4-methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide.